



1-800-533-1710

BA190

BCR/ABL1, p190, Quant, Monitor

PATIENT NAME TESTINGRNV, INTERFACE			ORDER NUMBER I109000353
PATIENT ID SA00119495	DATE OF BIRTH 01/01/1999	SEX Male	REQUESTED BY CLIENT CLIENT
COLLECTED 4/8/2019, 12:00 AM	RECEIVED 4/9/2019, 3:15 PM	REPORTED 4/9/2019, 3:48 PM	
7028846 DLMP Rochester Rochester MN 55901			CLIENT ORDER NUMBER SA00119495
			CLIENT MRN SA00119495

BCR/ABL1 p190 Result	see interpretation
Specimen Type	Peripheral blood

INTERPRETATION
Peripheral blood, <i>BCR/ABL1</i> mRNA level analysis (p190 fusion form):
Positive. <i>BCR/ABL1</i> p190 mRNA transcripts were detected and estimated to represent 30.0% of total ABL1 (%BCR/ABL1 (p190):ABL1).
Method summary: <i>BCR/ABL1</i> , p190 fusion: <i>BCR/ABL1</i> p190 mRNA transcript level was evaluated using quantitative, reverse transcription PCR. The detection limit for this assay is 0.01%. See Mayo Clinic Laboratories Test Catalog for additional method details. The assay detects the most common p190 fusion form (e1/a2), but does not detect other fusions, including the p210, which is the most common form found in chronic myelogenous leukemia. This assay should only be ordered for monitoring patients with a previously identified p190 fusion form. Test BADX (<i>BCR/ABL1</i> mRNA detection, RT-PCR, Quantitative, Diagnostic) should be ordered if the test is being performed in a diagnostic setting to identify the <i>BCR/ABL1</i> fusion form and test BCRAB (<i>BCR/ABL1</i> , p210, mRNA detection, RT-PCR, Quantitative, Monitoring CML) should be ordered if this patient is being monitored for a known p210 fusion form (e13a2 or e14a2). The reproducibility of this assay is such that results within 0.5 log should be considered equivalent. Trends in the level of <i>BCR/ABL1</i> mRNA should be followed and clinically significant changes verified with a subsequent specimen. Please contact the Mayo Molecular Hematopathology Laboratory at 855-516-8404 with questions or if additional testing is required.
Signing Pathologist: BENJAMIN BAILEY

DISCLAIMER
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

<u>CODE</u>	<u>LABORATORY</u>	<u>ADDRESS</u>
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW Rochester , MN 55905

The collected, received, and reported dates and times on the report are in the time zone of the performing location.

PATIENT NAME	TESTINGRNV, INTERFACE
---------------------	------------------------------